United Therapeutics (NASDAQ:UTHR) EVP Sells $4,586,248.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total value of $4,586,248.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $24,960,240.32. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $555.91 on Friday. The business has a fifty day moving average price of $558.34 and a two-hundred day moving average price of $527.84. The stock has a market capitalization of $23.60 billion, a PE ratio of 20.52, a P/E/G ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the company posted $6.63 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter worth about $317,617,000. Norges Bank acquired a new position in United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Finally, Bank of America lifted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.